183 related articles for article (PubMed ID: 32519566)
1. Acute changes in nerve excitability following oxaliplatin treatment in mice.
Makker PGS; White D; Lees JG; Parmar J; Goldstein D; Park SB; Howells J; Moalem-Taylor G
J Neurophysiol; 2020 Jul; 124(1):232-244. PubMed ID: 32519566
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
[TBL] [Abstract][Full Text] [Related]
4. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
5. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological investigation of motor axonal excitability in a mouse model of nerve constriction injury.
Makker PGS; Keating BA; Lees JG; Burke D; Howells J; Moalem-Taylor G
J Peripher Nerv Syst; 2021 Mar; 26(1):99-112. PubMed ID: 33432642
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
8. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
9. Cold aggravates abnormal excitability of motor axons in oxaliplatin-treated patients.
Bennedsgaard K; Ventzel L; Grafe P; Tigerholm J; Themistocleous AC; Bennett DL; Tankisi H; Finnerup NB
Muscle Nerve; 2020 Jun; 61(6):796-800. PubMed ID: 32133655
[TBL] [Abstract][Full Text] [Related]
10. Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.
Cerles O; Gonçalves TC; Chouzenoux S; Benoit E; Schmitt A; Bennett Saidu NE; Kavian N; Chéreau C; Gobeaux C; Weill B; Coriat R; Nicco C; Batteux F
Acta Neuropathol Commun; 2019 Jan; 7(1):9. PubMed ID: 30657060
[TBL] [Abstract][Full Text] [Related]
11. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
12. Nerve excitability differences in slow and fast motor axons of the rat: more than just
Bell JM; Lorenz C; Jones KE
J Neurophysiol; 2019 Oct; 122(4):1728-1734. PubMed ID: 31533011
[TBL] [Abstract][Full Text] [Related]
13. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
PLoS One; 2011 Apr; 6(4):e18469. PubMed ID: 21494615
[TBL] [Abstract][Full Text] [Related]
14. Upper and lower limb motor axons demonstrate differential excitability and accommodation to strong hyperpolarizing currents during induced hyperthermia.
Marmoy OR; Furlong PL; Moore CEG
J Neurophysiol; 2019 Jun; 121(6):2061-2070. PubMed ID: 30917073
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
Nasu S; Misawa S; Nakaseko C; Shibuya K; Isose S; Sekiguchi Y; Mitsuma S; Ohmori S; Iwai Y; Beppu M; Shimizu N; Ohwada C; Takeda Y; Fujimaki Y; Kuwabara S
Clin Neurophysiol; 2014 Feb; 125(2):381-7. PubMed ID: 23973385
[TBL] [Abstract][Full Text] [Related]
16. A unified model of the excitability of mouse sensory and motor axons.
Makker PGS; Matamala JM; Park SB; Lees JG; Kiernan MC; Burke D; Moalem-Taylor G; Howells J
J Peripher Nerv Syst; 2018 Sep; 23(3):159-173. PubMed ID: 29920851
[TBL] [Abstract][Full Text] [Related]
17. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
18. Changes in excitability properties associated with axonal regeneration in human neuropathy and mouse Wallerian degeneration.
Sawai S; Kanai K; Nakata M; Hiraga A; Misawa S; Isose S; Hattori T; Kuwabara S
Clin Neurophysiol; 2008 May; 119(5):1097-105. PubMed ID: 18342570
[TBL] [Abstract][Full Text] [Related]
19. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice.
Renn CL; Carozzi VA; Rhee P; Gallop D; Dorsey SG; Cavaletti G
Mol Pain; 2011 Apr; 7():29. PubMed ID: 21521528
[TBL] [Abstract][Full Text] [Related]
20. Hyperpolarization-activated cyclic-nucleotide-gated channels potentially modulate axonal excitability at different thresholds.
Weerasinghe D; Menon P; Vucic S
J Neurophysiol; 2017 Dec; 118(6):3044-3050. PubMed ID: 28904107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
